Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-21-000066
Filing Date
2021-11-05
Accepted
2021-11-05 09:08:21
Documents
6
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 2021 THIRD QUARTER 6-K q32021form6-k.htm 6-K 23094
2 EX-99.1 2021 THIRD QUARTER INTERIM FINANCIAL STATEMENTS ex991-interimfsseptember30.htm EX-99.1 436395
3 EX-99.2 2021 THIRD QUARTER MD&A ex992-q32021mda.htm EX-99.2 233807
4 EX-99.3 Q3 2021 CERTIFICATION CEO ex993-q32021certificationx.htm EX-99.3 14760
5 EX-99.4 Q3 2021 CERTIFICATION CFO ex994-q32021certificationx.htm EX-99.4 14657
6 oncolyticslogotaglinebluea.jpg GRAPHIC 355294
  Complete submission text file 0001129928-21-000066.txt   1163129
Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 211382616
SIC: 2834 Pharmaceutical Preparations